Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced that its CFO, EVP of Regulatory Affairs and Clinical Operations, and SVP of Corporate Communication will be presenting at the 25th Annual Needham Healthcare Conference on April 14, 2026. A webcast of the presentation will be available on the company's investor relations website for 30 days following the event. Amphastar Pharmaceuticals focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar CFO, regulatory chief to present April 14; replay lasts 30 days
Amphastar Pharmaceuticals (NASDAQ: AMPH) will present at the 25th Annual Needham Healthcare Conference on April 14, 2026, at 11:45 am ET. Executives Bill Peters (CFO), Tony Marrs (EVP Regulatory & Clinical), and Dan Dischner (SVP Corporate Communication) will speak. The presentation will be streamed via webcast and available for 30 days on Amphastar's investor website.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?
Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its share price drop below its 200-day moving average, trading at $19.59 on heavy volume, indicating a bearish technical shift. Analysts have maintained a consensus "Hold" rating with an average price target of $29.50, despite some recent price target reductions. The company also missed its quarterly earnings estimates, reporting EPS of $0.73 against an expected $0.97 and revenue of $183.1 million against estimates of $190.5 million.
Vanguard amends Schedule 13G/A — AMPH (Vanguard reports 0 shares)
The Vanguard Group has filed an amended Schedule 13G/A for Amphastar Pharmaceuticals Inc. (AMPH), reporting zero beneficial ownership of common stock. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately in accordance with SEC Release No. 34-39538. The filing explicitly states that this is a reporting adjustment and not an indication of a sale or a change in economic ownership.
[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity
Amphastar Pharmaceuticals, Inc. (AMPH) reported insider share movements related to tax withholding on vested restricted stock units. Executives Jack Y. Zhang and Mary Z. Luo disposed of 12,692 shares in total at $18.18 per share to cover tax liabilities, which is classified as a tax-withholding disposition rather than an open-market sale. Following these transactions, both executives maintain substantial equity positions in the company.
Tax withholding on RSU vesting for Amphastar (AMPH) CFO Peters
Amphastar Pharmaceuticals CFO William J. Peters reported a routine tax-related share disposition where 1,973 shares of common stock were withheld to satisfy tax liability upon RSU vesting. This non-discretionary event occurred at a price of $18.18 per share, and Peters now directly holds 175,063 shares of Amphastar common stock. The transaction is identified as a compensation-driven, tax-withholding event rather than an open-market sale.
Tax withholding trims Amphastar (NASDAQ: AMPH) exec's RSU shares
Amphastar Pharmaceuticals senior executive Rong Zhou reported a routine tax-withholding share disposition involving 1,225 shares of common stock valued at $18.18 each to cover tax liabilities from restricted stock unit vesting. Following this transaction, Zhou directly holds 171,554 Amphastar shares, with additional indirect holdings through the Zhou Family Trust and his spouse. This transaction was a tax-related withholding and not a discretionary open-market sale.
Amphastar Pharmaceuticals Inc authorizes $50 million increase to share buyback program on March 12, 2026 - SEC filing
Amphastar Pharmaceuticals Inc. has authorized a $50 million increase to its share buyback program, effective March 12, 2026, as disclosed in a recent SEC filing. The biopharmaceutical company focuses on developing, manufacturing, and selling challenging generic and injectable products, with a robust pipeline of over 20 product candidates. This move signals the company's confidence in its financial position and future prospects.
Amphastar Pharmaceuticals Inc - Authorizes $50 Million Increase To Share Buyback Program On March 12, 2026 - SEC Filing
Amphastar Pharmaceuticals Inc. has announced a $50 million increase to its share buyback program, effective March 12, 2026, as detailed in an SEC filing. This move indicates the company's decision to return capital to shareholders through stock repurchases. The news was reported by Reuters via Refinitiv.
Amphastar Expands Share Repurchase Authorization to Manage Equity
Amphastar Pharmaceuticals' board has approved a $50 million increase to its share buyback program, intending to manage its equity structure and offset dilution from equity compensation. The timing and execution of these repurchases will depend on various factors including share price and market conditions. TipRanks' AI Analyst, Spark, rates AMPH as Neutral due to weakening financial fundamentals and bearish technicals, despite a reasonable P/E valuation and cautiously positive earnings outlook.
Amphastar Pharmaceuticals boosts buyback program by $50 million
Amphastar Pharmaceuticals (AMPH) has announced a $50 million increase to its existing share repurchase program. This move is intended to offset dilution from equity compensation. The buyback will continue indefinitely and can occur through various methods, including open market purchases and Rule 10b5-1 plans.
Amphastar (NASDAQ: AMPH) adds $50 million to share buyback program
Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that its Board of Directors authorized a $50 million increase to its share buyback program, effective March 12, 2026. The primary goal of this expanded program is to offset dilution caused by equity compensation grants over time. Repurchases will be made through various legal methods, with the timing and volume depending on market conditions and regulatory requirements, and the program has an indefinite duration.
Clark Capital Management Group Inc. Invests $7.56 Million in Amphastar Pharmaceuticals, Inc. $AMPH
Clark Capital Management Group Inc. has acquired a new stake worth $7.56 million in Amphastar Pharmaceuticals, Inc. during the third quarter. This investment is part of broader institutional interest, with other hedge funds also adjusting their positions in AMPH. Analysts currently hold a "Hold" rating for Amphastar Pharmaceuticals, with an average target price of $29.50, despite recent price objective reductions.
Algert Global LLC Acquires 268,612 Shares of Amphastar Pharmaceuticals, Inc. $AMPH
Algert Global LLC significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 216.1% in the third quarter, acquiring an additional 268,612 shares. This brought their total holdings to 392,902 shares, valued at approximately $10.47 million. Other institutional investors also boosted their positions, while one executive insider sold shares.
Amphastar (AMPH) EVP Yakob has 1,033 shares withheld for RSU tax
Amphastar Pharmaceuticals EVP Liawatidewi Yakob had 1,033 shares withheld on March 15, 2026, to cover tax liabilities associated with the vesting of Restricted Stock Units (RSUs). This transaction, valued at $18.18 per share, is a non-market disposition for tax purposes. After the withholding, Yakob directly holds 121,892 shares and indirectly holds 2,459 shares through the Yakob and Sunmoon Trust.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of "Hold" from Analysts
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has received an average "Hold" rating from analysts, with six of eight brokers assigning a hold and two a buy. The average one-year target price stands at $29.50, though several firms recently lowered their price targets to around $30. The company missed recent quarterly earnings and revenue estimates, and shares are currently trading near their 52-week low.
Amphastar (AMPH) exec granted RSUs, options and reports tax share withholding
Amphastar Pharmaceuticals executive Rong Zhou was granted 39,432 Restricted Stock Units (RSUs) and an option for 81,341 shares of common stock, both vesting annually over four years starting March 9, 2027. Additionally, 2,215 shares were withheld to cover taxes on RSU vesting, which is noted as a tax-withholding disposition rather than an open-market sale. Following these transactions, Zhou's total direct and indirect common shareholdings, including family trusts and spouse holdings, amount to 277,447, alongside the new option award.
Amphastar (NASDAQ: AMPH) EVP receives RSUs and stock option grant
Amphastar Pharmaceuticals EVP Liawatidewi Yakob received restricted stock units (RSUs) for 35,450 shares and employee stock options for 73,126 shares. Both the RSUs and options begin vesting in four equal annual installments starting March 9, 2027. Additionally, 1,870 shares were withheld to cover tax liabilities related to RSU vesting.
Amphastar (AMPH) CFO granted RSUs, stock options and withholds shares for taxes
Amphastar Pharmaceuticals CFO William J. Peters received new equity compensation, including 58,693 restricted stock units (RSUs) and an option for 121,071 shares, both vesting in annual installments starting March 9, 2027. He also had 3,297 shares withheld to cover tax liabilities associated with RSU vesting. Following these transactions, Peters directly holds 177,036 shares of Amphastar Common Stock.
Amphastar (AMPH) CEO logs 10,850-share RSU tax withholding, retains large stake
Amphastar Pharmaceuticals CEO Jack Y. Zhang reported a routine tax-related withholding of 10,850 shares of common stock on March 6, 2026, to cover tax liabilities from restricted stock unit vesting. This was a tax withholding, not an open-market sale, and is considered an administrative compensation-related event. After this transaction, Zhang still holds a substantial stake, including 2,834,117 directly owned shares and significant indirect holdings through his spouse and Applied Physics and Chemistry Laboratories, Inc.
[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity
A recent Form 4 filing for Amphastar Pharmaceuticals, Inc. (AMPH) shows that senior executive Rong Zhou had a small share disposition. This transaction, which involved 1,124 shares withheld at $19.96 each to cover tax liability related to RSU vesting, was not an open-market sale. Following this, Zhou directly holds 136,919 shares, with additional shares held indirectly through a family trust and by a spouse.
AMPH SEC Filings - Amphastar Pharma 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Amphastar Pharmaceuticals (AMPH) SEC filings, including 10-K, 10-Q, and 8-K forms, offering detailed insights into the company's operations, financial performance, and material events. It highlights recent filings such as a license agreement with Nanjing Anji (up to $267M in milestones) and insider trading disclosures, using AI-powered summaries to explain their significance. The platform also provides real-time updates and market data for AMPH.
Amphastar Pharmaceuticals signs new executive employment agreements
Amphastar Pharmaceuticals (NASDAQ: AMPH) has entered into new one-year executive employment agreements with Jacob Liawatidewi and Rong Zhou. Both executives will receive substantial base salaries, performance-based cash bonuses, and equity incentive compensation. The company's stock is currently trading near its 52-week low, but InvestingPro analysis suggests it is undervalued with a potential upside of 57%.
Vanguard Group Inc. Has $70.12 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH
Vanguard Group Inc. decreased its stake in Amphastar Pharmaceuticals by 2.1% in Q3, holding shares valued at $70.12 million. Insider selling was also noted, with executives selling a total of 13,950 shares. Amphastar Pharmaceuticals missed Q4 earnings and revenue estimates and currently holds a "Hold" consensus rating with an average target price of $29.50.
Amphastar Pharmaceuticals signs new executive employment agreements
Amphastar Pharmaceuticals (NASDAQ: AMPH) has entered into new one-year executive employment agreements with Jacob Liawatidewi and Rong Zhou, effective this week. The agreements outline their base salaries, performance-based bonuses, and eligibility for equity incentive compensation, with provisions for termination and change in control. Despite recent financial results falling short of analyst expectations, the company's stock is trading near its 52-week low but is considered undervalued by InvestingPro analysis.
According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Amphastar Pharmaceuticals Inc has signed a five-year supply agreement, under which all payments will be settled in RMB.
Amphastar Pharmaceuticals Inc. has signed a five-year supply agreement, with all payments to be settled in RMB, as disclosed in SEC documents. This agreement signifies a long-term partnership and reflects the increasing adoption of RMB for cross-border trade, helping to mitigate exchange rate risks and improve transaction efficiency. The deal also provides revenue stability for Amphastar Pharmaceuticals and highlights its international business strategy.
Amphastar Pharmaceuticals Stock Plummets to New 52-Week Low of $19.83
Amphastar Pharmaceuticals, Inc. has reached a new 52-week low of $19.83, marking a significant decline over the past year. The company's stock price has dropped by 51.42% while the S&P 500 gained 17.36%. With a market capitalization of $1,541 million and a P/E ratio of 9.00, investors are closely watching its future trajectory.
Generic Pharmaceuticals Stocks Q4 Highlights: Amphastar Pharmaceuticals (NASDAQ:AMPH)
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported a disappointing Q4 with revenues down 1.8% year-on-year, missing analyst estimates, leading to a 23.7% stock drop. In contrast, ANI Pharmaceuticals (NASDAQ:ANIP) delivered strong Q4 results with revenues up 29.6%, beating expectations, though its stock traded sideways post-reporting. The article also reviews Q4 performance for Amneal Pharmaceuticals and Viatris, highlighting the competitive generic pharmaceutical industry's challenges and tailwinds.
Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference
Amphastar Pharmaceuticals announced that its CFO, Bill Peters, and SVP of Corporate Communication, Dan Dischner, will be presenting at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, at 1:30 PM ET. A webcast of the presentation will be available on the company's investor relations website for 30 days. Amphastar is a biopharmaceutical company focused on developing, manufacturing, and marketing challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and SVP of Corp. Communication Dan Dischner will present at the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 1:30 pm ET. A webcast of the presentation will be available on the company's investor relations website for 30 days. Amphastar specializes in developing, manufacturing, and marketing technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
Cash per share of Amphastar Pharmaceuticals, Inc. – DUS:29A
This article provides financial information for Amphastar Pharmaceuticals, Inc. (DUS:29A) on the TradingView platform. It highlights the cash per share value, along with other financial data, stock market performance, and company details available to users. The content itself seems to be a template or header for financial data rather than a detailed analysis.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2025 Earnings Call Transcript
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q4 2025 earnings, missing expectations with an EPS of $0.73 against an anticipated $0.97. The company highlighted strong performance from BAQSIMI and new product approvals like ipratropium bromide HFA inhalation aerosol, which is expected to be a significant growth driver in 2026. Despite revenue headwinds from legacy products, Amphastar outlined plans for continued pipeline expansion, including insulin aspart and GLP-1 programs, and anticipates mid-to-high single-digit revenue growth for 2026.
BAQSIMI sales jump 46% as Amphastar profit falls in 2025
Amphastar Pharmaceuticals reported Q4 2025 net revenues of $183.1 million and fiscal 2025 net revenues of $719.9 million. While BAQSIMI sales saw a significant 46% year-over-year increase, GAAP net income and diluted EPS decreased compared to the previous year, partly due to a $23.1 million legal settlement and increased R&D and G&A expenses. The market reacted negatively to the news, causing AMPH stock to decline by 23.63%.
BAQSIMI® growth offsets weaker 2025 earnings at Amphastar (NASDAQ: AMPH)
Amphastar Pharmaceuticals reported a decline in profits for the fourth quarter and full-year 2025, despite strong revenue growth from its BAQSIMI® product. Full-year net revenues slightly decreased, and GAAP net income significantly dropped due to increased operating expenses and lower gross margins. The company highlighted FDA approvals for new products and expansion of its proprietary pipeline as key strategic developments for long-term growth.
Amphastar Pharmaceuticals (AMPH) Margin Compression Reinforces Bearish Narratives Despite Low 9.5x P/E
Amphastar Pharmaceuticals (AMPH) faces margin compression, with its net profit margin decreasing from 21.8% to 13.6% over the last year, reinforcing bearish arguments despite the company's low 9.5x P/E ratio. Analysts highlight a potential 54.3% upside based on the discounted valuation and historical earnings growth, but forecast revenue and earnings growth remain below the broader U.S. market, leading to a mixed outlook. Investors are focused on the efficiency of revenue conversion into profit and the quality of earnings given these challenging trends.
TD Asset Management Inc Sells 103,038 Shares of Amphastar Pharmaceuticals, Inc. $AMPH
TD Asset Management Inc. reduced its stake in Amphastar Pharmaceuticals by 5.1%, selling 103,038 shares, now owning 1,931,892 shares valued at $51.49 million. This sale follows Amphastar's Q4 results missing expectations, leading to an 11.7% stock decline, despite management outlining mid-to-high single-digit revenue growth for fiscal 2026 and launching a new respiratory product. Institutional investors hold 65.09% of the company's stock, and recent insider transactions show sales by a director and EVP.
Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today
Amphastar Pharmaceuticals (AMPH) shares fell significantly after the company reported fourth-quarter 2025 financial results that missed Wall Street's expectations for both revenue and profit. The company's revenue declined year-on-year, and adjusted earnings per share also fell short of estimates, with operating margins contracting. These results indicated slowing growth and weakening profitability, leading to investor disappointment.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 CY2025 Revenue Estimates, Stock Drops 11.7%
Amphastar Pharmaceuticals (NASDAQ:AMPH) missed its Q4 CY2025 revenue and non-GAAP profit estimates, reporting sales of $183.1 million and adjusted EPS of $0.73, leading to an 11.7% stock drop. The company's revenue declined 1.8% year-on-year, and its operating margin decreased. Despite a strong five-year compounded annual growth rate in sales and EPS, recent performance shows a deceleration in revenue growth and a contraction in operating margin.
Amphastar Pharmaceuticals Reports Financial Results for Q4 and Full Year 2025
Amphastar Pharmaceuticals announced its financial results for Q4 and full year 2025, showing decreased net revenues and net income compared to 2024. Despite this, BAQSIMI® sales saw significant growth, while Epinephrine and Glucagon sales declined due to increased competition. The company continues to focus on pipeline expansion, manufacturing scale-up, and strategic initiatives for future growth.
Amphastar (AMPH) Q4 2025 Earnings Call Transcript
Amphastar Pharmaceuticals reported Q4 2025 results, highlighting significant FDA approvals for products like ipratropium bromide HFA with 180 days of exclusivity, and the expansion of their proprietary pipeline into oncology, ophthalmology, and immunology. The company expects mid-to-high single-digit revenue growth in 2026, driven by new product launches, but anticipates lower gross margins and increased operational and R&D spending. They also discussed strategic investments in manufacturing expansion and ongoing buyback programs.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
Amphastar Pharmaceuticals reported its financial results for the three months and full year ended December 31, 2025, with net revenues of $183.1 million and $719.9 million, respectively. The company highlighted BAQSIMI® as a key revenue driver with double-digit growth and noted FDA approvals for iron sucrose and teriparatide injections, showcasing its capabilities in complex generics. Dr. Jack Zhang, President and CEO, emphasized the company's focus on commercial strength and scientific innovation, including expanding its presence in oncology, ophthalmology, and immunology with new peptides and a corticotropin compound.
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar Pharmaceuticals (AMPH) reported Q4 earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.97 and falling short of $0.92 per share from the previous year. The company's revenues for the quarter ended December 2025 were $183.11 million, also below the Zacks Consensus Estimate. Due to an unfavorable estimate revisions trend, the stock currently holds a Zacks Rank #4 (Sell).
Earnings Flash (AMPH) Amphastar Pharmaceuticals, Inc. Reports Q4 Revenue $183.1M, vs. FactSet Est of $190.1M
Amphastar Pharmaceuticals, Inc. (AMPH) reported its Q4 revenue for 2025 as $183.1 million, falling short of FactSet's estimated $190.1 million. The company's stock experienced a 5.29% decline over 5 days and a 7.18% decline year-to-date. This news follows several other recent updates, including FDA approvals for new drug applications and changes in analyst price targets.
Amphastar Pharmaceuticals Inc. (AMPH) stock falls on Q4 2025 Earnings
Amphastar Pharmaceuticals Inc. (AMPH) reported Q4 2025 revenues of $183.1 million, missing analyst consensus and leading to a significant 17.3% drop in stock price. The company's key financial metrics, including revenue, gross profit, operating profit, and net income, all saw year-over-year declines. Insider trading activity showed more sales than purchases, while institutional investors had mixed reactions, with some adding and others decreasing their positions.
Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect
Amphastar Pharmaceuticals (AMPH) is set to report earnings tomorrow after market hours. The company beat revenue and EPS expectations last quarter but the market anticipates flat year-on-year revenue for the upcoming report. Analysts have reconfirmed their estimates, and the stock is trading with an average analyst price target higher than its current share price.
Amphastar Announces FDA Approval for Ipratropium Bromide HFA
Amphastar Pharmaceuticals announced FDA approval for its Ipratropium Bromide HFA Inhalation Aerosol, which is bioequivalent to Atrovent HFA. The company secured 180 days of generic exclusivity as the first Paragraph IV ANDA filer and plans to launch the product in early Q2 2026. This approval targets a market with approximately $112 million in annual U.S. sales and strengthens Amphastar's respiratory portfolio.
(AMPH) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH), highlighting strong near and mid-term sentiment that could extend long-term. It identifies a mid-channel oscillation pattern and an exceptional 36.8:1 risk-reward short setup. The analysis offers three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and AI-generated support and resistance levels.
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
Amphastar Pharmaceuticals, Inc. announced it will release its fourth quarter 2025 financial results after market close on Thursday, February 26, 2026. The company will also host a conference call at 2:00 p.m. Pacific Time to discuss these results. Interested parties can access the call via a toll-free number or through the Investors page on Amphastar's website, with a webcast replay available within 24 hours.
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced it will release its fourth-quarter 2025 financial results after the market closes on Thursday, February 26, 2026. The company will also host a conference call at 2:00 p.m. Pacific Time on the same day to discuss these results. Interested parties can access the call via a toll-free number or through the investors page on Amphastar's website.
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced it will release its fourth-quarter 2025 financial results after the market closes on Thursday, February 26, 2026. The company will also host a conference call at 2:00 p.m. Pacific Time to discuss these results. Interested parties can access the call via a toll-free number or the company's website, with a webcast replay available within 24 hours.
